L. En-france and . Données, , 2015.

J. Ferlay, I. Soerjomataram, R. Dikshit, S. Eser, C. Mathers et al., Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012, Int J Cancer. 1 mars, vol.136, issue.5, pp.359-86, 2015.

, Melanoma of the Skin Cancer Stat Facts

J. Lee, R. Kefford, and M. Carlino, PD-1 and PD-L1 inhibitors in melanoma treatment: past success, present application and future challenges, Immunotherapy. juin, vol.8, issue.6, pp.733-779, 2016.

S. L. Topalian, F. S. Hodi, J. R. Brahmer, S. N. Gettinger, D. C. Smith et al.,

, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer, N Engl J Med. 28 juin, vol.366, issue.26, pp.2443-54, 2012.

A. Eggermont, M. Maio, and C. Robert, Immune checkpoint inhibitors in melanoma provide the cornerstones for curative therapies, Semin Oncol. juin, vol.42, issue.3, pp.429-464, 2015.

S. Gandini, D. Massi, and M. Mandalà, PD-L1 expression in cancer patients receiving anti PD

/. Antibodies, A systematic review and meta-analysis, Crit Rev Oncol Hematol. avr, vol.100, pp.88-98, 2016.

J. M. Taube, A. Klein, J. R. Brahmer, H. Xu, X. Pan et al., Association of PD-1, p.1

, other features of the tumor immune microenvironment with response to anti-PD-1 therapy, Clin Cancer Res Off J Am Assoc Cancer Res, vol.20, pp.5064-74, 2014.

D. Massi, D. Brusa, B. Merelli, M. Ciano, V. Audrito et al., PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics

, Ann Oncol Off J Eur Soc Med Oncol. déc, vol.25, issue.12, pp.2433-2475, 2014.

Q. Wang, F. Liu, and L. Liu, Prognostic significance of PD-L1 in solid tumor: An updated meta-analysis. Medicine (Baltimore), vol.96, p.6369, 2017.

R. Hino, K. Kabashima, Y. Kato, H. Yagi, M. Nakamura et al., Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma, Cancer. 1 avr, vol.116, issue.7, pp.1757-66, 2010.

H. M. Kluger, C. R. Zito, M. L. Barr, M. K. Baine, V. Chiang et al., Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites, Clin Cancer Res Off J Am Assoc Cancer Res. 1 juill, vol.21, issue.13, p.60, 2015.

R. S. Herbst, J. Soria, M. Kowanetz, G. D. Fine, O. Hamid et al., Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients, Nature, vol.515, issue.7528, p.5637, 2014.

P. C. Tumeh, C. L. Harview, J. H. Yearley, I. P. Shintaku, E. Taylor et al., PD-1 blockade induces responses by inhibiting adaptive immune resistance, Nature, vol.515, issue.7528, pp.568-71, 2014.

M. Teng, S. F. Ngiow, A. Ribas, and M. J. Smyth, Classifying Cancers Based on T-cell Infiltration and PD-L1, Cancer Res. 1 juin, vol.75, issue.11, p.213945, 2015.

J. M. Taube, R. A. Anders, G. D. Young, H. Xu, R. Sharma et al., Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape, Sci Transl Med. 28 mars, vol.4, issue.127, pp.127-164, 2012.

J. D. Wolchok, H. Kluger, M. K. Callahan, M. A. Postow, N. A. Rizvi et al.,

, Nivolumab plus ipilimumab in advanced melanoma, N Engl J Med. 11 juill, vol.369, issue.2, p.33, 2013.

J. Larkin, V. Chiarion-sileni, R. Gonzalez, J. J. Grob, C. L. Cowey et al., Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma, N Engl J Med. 2 juill, vol.373, issue.1, p.2334, 2015.

C. Robert, G. V. Long, B. Brady, C. Dutriaux, M. Maio et al., Nivolumab in previously untreated melanoma without BRAF mutation, N Engl J Med. 22 janv, vol.372, issue.4, p.32030, 2015.

J. S. Weber, S. P. Angelo, D. Minor, F. S. Hodi, R. Gutzmer et al., Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, Lancet Oncol. avr, vol.16, issue.4, p.37584, 2015.

M. I. Ilie, S. Lassalle, E. Long-mira, C. Bonnetaud, O. Bordone et al., Diagnostic value of immunohistochemistry for the detection of the BRAF(V600E) mutation in papillary thyroid carcinoma: comparative analysis with three DNA-based assays, Thyroid Off J Am Thyroid Assoc. mai, vol.24, issue.5, p.85866, 2014.

M. S. Lawrence, P. Stojanov, P. Polak, G. V. Kryukov, K. Cibulskis et al., Mutational heterogeneity in cancer and the search for new cancer-associated genes, Nature. 11 juill, vol.499, issue.7457, p.2148, 2013.

L. Chen and D. B. Flies, Molecular mechanisms of T cell co-stimulation and co-inhibition, Nat Rev Immunol. avr, vol.13, issue.4, p.42, 2013.

S. Berry and J. M. Taube, Adaptive: PD-L1-mediated immune resistance by melanoma. Oncoimmunology, vol.4, p.1029704, 2015.

A. R. Hansen and L. L. Siu, PD-L1 Testing in Cancer: Challenges in Companion Diagnostic Development, JAMA Oncol. janv, 2016.

J. Madore, R. E. Vilain, A. M. Menzies, H. Kakavand, J. S. Wilmott et al., PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials, J Clin Oncol Off J Am Soc Clin Oncol. déc, vol.28, issue.3, pp.4102-4111, 2015.

A. L. Burton, B. A. Roach, M. P. Mays, A. F. Chen, B. Ginter et al., Prognostic significance of tumor infiltrating lymphocytes in melanoma, Am Surg. févr, vol.77, issue.2, p.92, 2011.

N. Lee, L. R. Zakka, M. C. Mihm, and T. Schatton, Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy, Pathology (Phila). févr, vol.48, issue.2, p.87, 2016.

C. G. Clemente, M. C. Mihm, R. Bufalino, S. Zurrida, P. Collini et al., Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma, Cancer. 1 avr, vol.77, issue.7, p.130310, 1996.

A. I. Daud, K. Loo, M. L. Pauli, R. Sanchez-rodriguez, P. M. Sandoval et al., Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma, J Clin Invest. 1 sept, vol.126, issue.9, p.344752, 2016.

R. M. Chabanon, M. Pedrero, C. Lefebvre, A. Marabelle, J. Soria et al.,

, Mutational Landscape and Sensitivity to Immune Checkpoint Blockers, Clin Cancer Res Off J Am Assoc Cancer Res. 1 sept, vol.22, issue.17, pp.4309-4330, 2016.

, Je promets et je jure d'être fidèle aux lois de l'Honneur et de la probité dans l'exercice de la Médecine

, Je donnerais mes soins gratuitement à l'indigent et n'exigerai jamais un salaire au dessus de mon travail

, Admis dans l'intimité des maisons, mes yeux n'y verront pas ce qui s'y passe

, Je ne permettrai pas que des considérations de religion, de nation, de race, de parti ou de classe sociale viennent s'interposer entre mon Devoir et mon Patient

, Je garderai le respect absolu de la vie humaine. Même sous la menace

, Que les hommes m'accordent leur estime si je suis fidèle à mes promesses, Que je sois couvert d'opprobre et méprisé de mes confrères si j'y manque